323 related articles for article (PubMed ID: 30479461)
21. Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy.
Mollica Poeta V; Massara M; Capucetti A; Bonecchi R
Front Immunol; 2019; 10():379. PubMed ID: 30894861
[TBL] [Abstract][Full Text] [Related]
22. Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers.
Do HTT; Lee CH; Cho J
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991604
[TBL] [Abstract][Full Text] [Related]
23. Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance.
Tuomisto AE; Mäkinen MJ; Väyrynen JP
World J Gastroenterol; 2019 Aug; 25(31):4383-4404. PubMed ID: 31496619
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of the expression and prognostic value of CXC chemokines in colorectal cancer.
Yu L; Yang X; Xu C; Sun J; Fang Z; Pan H; Han W
Int Immunopharmacol; 2020 Dec; 89(Pt B):107077. PubMed ID: 33068862
[TBL] [Abstract][Full Text] [Related]
25. The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors-A Review of Literature.
Korbecki J; Kojder K; Kapczuk P; Kupnicka P; Gawrońska-Szklarz B; Gutowska I; Chlubek D; Baranowska-Bosiacka I
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467722
[TBL] [Abstract][Full Text] [Related]
26. CXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer.
Nagaya N; Lee GT; Horie S; Kim IY
Front Mol Biosci; 2020; 7():579874. PubMed ID: 33195424
[TBL] [Abstract][Full Text] [Related]
27. CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition.
Lu Y; Dong B; Xu F; Xu Y; Pan J; Song J; Zhang J; Huang Y; Xue W
Cell Commun Signal; 2019 Sep; 17(1):118. PubMed ID: 31500632
[TBL] [Abstract][Full Text] [Related]
28. CXCL1 stimulates migration and invasion in ER‑negative breast cancer cells via activation of the ERK/MMP2/9 signaling axis.
Yang C; Yu H; Chen R; Tao K; Jian L; Peng M; Li X; Liu M; Liu S
Int J Oncol; 2019 Sep; 55(3):684-696. PubMed ID: 31322183
[TBL] [Abstract][Full Text] [Related]
29. RIP3 promotes colitis-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression.
Liu ZY; Zheng M; Li YM; Fan XY; Wang JC; Li ZC; Yang HJ; Yu JM; Cui J; Jiang JL; Tang J; Chen ZN
Theranostics; 2019; 9(12):3659-3673. PubMed ID: 31281505
[No Abstract] [Full Text] [Related]
30. Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8-CXCR2 Axis.
Ogawa R; Yamamoto T; Hirai H; Hanada K; Kiyasu Y; Nishikawa G; Mizuno R; Inamoto S; Itatani Y; Sakai Y; Kawada K
Clin Cancer Res; 2019 May; 25(9):2887-2899. PubMed ID: 30705034
[TBL] [Abstract][Full Text] [Related]
31. Exosome-encapsulated miRNAs contribute to CXCL12/CXCR4-induced liver metastasis of colorectal cancer by enhancing M2 polarization of macrophages.
Wang D; Wang X; Si M; Yang J; Sun S; Wu H; Cui S; Qu X; Yu X
Cancer Lett; 2020 Apr; 474():36-52. PubMed ID: 31931030
[TBL] [Abstract][Full Text] [Related]
32. CXCR4 as a prognostic biomarker in gastrointestinal cancer: a meta-analysis.
Jiang Q; Sun Y; Liu X
Biomarkers; 2019 Sep; 24(6):510-516. PubMed ID: 31244335
[No Abstract] [Full Text] [Related]
33. Immunotherapy in colorectal cancer: rationale, challenges and potential.
Ganesh K; Stadler ZK; Cercek A; Mendelsohn RB; Shia J; Segal NH; Diaz LA
Nat Rev Gastroenterol Hepatol; 2019 Jun; 16(6):361-375. PubMed ID: 30886395
[TBL] [Abstract][Full Text] [Related]
34. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands.
Korbecki J; Grochans S; Gutowska I; Barczak K; Baranowska-Bosiacka I
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076281
[TBL] [Abstract][Full Text] [Related]
35. The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment.
Bikfalvi A; Billottet C
Am J Physiol Cell Physiol; 2020 Mar; 318(3):C542-C554. PubMed ID: 31913695
[TBL] [Abstract][Full Text] [Related]
36. A chemokine/chemokine receptor signature potentially predicts clinical outcome in colorectal cancer patients.
Mitchell A; Hasanali SL; Morera DS; Baskar R; Wang X; Khan R; Talukder A; Li CS; Manoharan M; Jordan AR; Wang J; Bollag RJ; Singh N; Albo D; Ghosh S; Lokeshwar VB
Cancer Biomark; 2019; 26(3):291-301. PubMed ID: 31524146
[TBL] [Abstract][Full Text] [Related]
37. The role of CXCL chemokine family in the development and progression of gastric cancer.
Chen X; Chen R; Jin R; Huang Z
Int J Clin Exp Pathol; 2020; 13(3):484-492. PubMed ID: 32269686
[TBL] [Abstract][Full Text] [Related]
38. Plasma IFN-γ-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma.
Qian L; Yu S; Yin C; Zhu B; Chen Z; Meng Z; Wang P
Pancreatology; 2019 Mar; 19(2):340-345. PubMed ID: 30685120
[TBL] [Abstract][Full Text] [Related]
39. Construction of a CXC Chemokine-Based Prediction Model for the Prognosis of Colon Cancer.
Liu K; Lai M; Wang S; Zheng K; Xie S; Wang X
Biomed Res Int; 2020; 2020():6107865. PubMed ID: 32337262
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the Prognosis and Therapeutic Value of the CXC Chemokine Family in Head and Neck Squamous Cell Carcinoma.
Li Y; Wu T; Gong S; Zhou H; Yu L; Liang M; Shi R; Wu Z; Zhang J; Li S
Front Oncol; 2020; 10():570736. PubMed ID: 33489879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
